Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. reports developments as a commercial messenger RNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. Its news commonly covers pipeline progress for cystic fibrosis and ornithine transcarbamylase deficiency programs, including LUNAR-CF, ARCT-032, LUNAR-OTC and ARCT-810, as well as updates tied to its LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies.
Company updates also address KOSTAIVE COVID-19 vaccine activity, partnered vaccine programs with CSL Seqirus, the ARCALIS manufacturing joint venture in Japan, collaboration revenue, research and development spending, quarterly financial results, investor conference participation, and executive or board changes.
Arcturus Therapeutics (Nasdaq:ARCT), a messenger RNA medicines company focused on liver and respiratory rare diseases, will present at the 2026 Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Thursday, June 4, 2026 at 9:20 a.m. ET, with a webcast available via the company’s investor relations website.
Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 2026 results and pipeline updates on May 7, 2026. Cash, cash equivalents and restricted cash were $213.4M at March 31, 2026, vs $232.8M at Dec 31, 2025, providing a runway beyond Q2 2028. The company initiated enrollment for a 12‑week Phase 2 inhaled mRNA CF study (up to 20 Class I subjects) and received FDA Type C guidance on pediatric strategy for OTC deficiency ahead of an EOP2 meeting in H2 2026. Q1 revenue declined and net loss widened to $27.0M (loss per share $(0.95)). Executive hires added a new CMO and CFO.
Arcturus Therapeutics (Nasdaq: ARCT) will report first quarter 2026 financial results after market close on May 7, 2026 and host a conference call and webcast the same day at 4:30 p.m. ET. Dial-in numbers and a webcast link are provided for investors and analysts.
Arcturus Therapeutics (Nasdaq: ARCT) will participate in the Leerink Partners 2026 Global Healthcare Conference in Miami with a fireside chat on Wednesday, March 11, 2026 at 11:20 a.m. ET.
The event will be webcast; investors can find the webcast link under the company's Investor Relations > Events section.
Summary not available.
Arcturus Therapeutics (Nasdaq: ARCT) will release fourth quarter and fiscal year 2025 financial results after market close on Tuesday, March 3, 2026. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on March 3, 2026 for a corporate update.
Dial-in numbers and a webcast link are provided for investor access; Conference ID: ARCTURUS.
Arcturus Therapeutics (Nasdaq: ARCT) announced that Joseph Payne, President & CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 5:15 p.m. Pacific Time. The company is a commercial messenger RNA medicines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines.
Arcturus Therapeutics (Nasdaq: ARCT) will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 12:30 p.m. ET.
The company is a commercial messenger RNA medicines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines.
Arcturus Therapeutics (Nasdaq: ARCT) reported Q3 2025 results and program updates on November 10, 2025. Revenue for Q3 was $17.2M and $74.8M for the nine months, declines of $24.5M and $54.7M year-over-year driven by lower CSL collaboration activity. Operating expenses were $33.7M in Q3 (down from $52.4M). Net loss for Q3 was $13.5M or ($0.49) per diluted share; nine-month net loss was $36.7M.
Clinical: interim Phase 2 ARCT-032 CF data showed mucus-burden reductions in 4 of 6 Class I participants; a 12-week, up-to-20-participant study is planned for H1 2026. Cash and equivalents were $237.3M with runway extended into 2028 after Q4 cost reductions.
Arcturus Therapeutics (Nasdaq: ARCT) will participate in two investor events in November 2025: a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 11:30 a.m. ET, and one-on-one meetings at the Jefferies Global Healthcare Conference in London from November 17–20, 2025 (GMT). The appearances provide scheduled opportunities for investor engagement and updates on the company’s commercial mRNA programs in liver, respiratory rare diseases, and infectious disease vaccines.